Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | -113.59%-95.27K | -27.14%-58.54K | 20.17%-51.03K | 45.80%-176.21K | 81.97%-21.65K | -3.18%-44.6K | 54.29%-46.05K | -4.66%-63.92K | -149.15%-325.14K | -595.22%-120.09K |
| Net income from continuing operations | -183.20%-89.73K | -11.39%-63.24K | -7.85%-59.67K | 52.18%-168.15K | 82.30%-24.37K | 38.90%-31.69K | 48.20%-56.77K | -5.41%-55.32K | -162.28%-351.6K | -412.28%-137.66K |
| Depreciation and amortization | -20.00%40 | 60.00%80 | --0 | -21.34%199 | -20.97%49 | -13.79%50 | -24.24%50 | -25.37%50 | -19.17%253 | -20.51%62 |
| Other non cashItems | ---- | ---- | ---- | 100.02%1 | ---- | ---- | ---- | ---- | ---6K | ---- |
| Change In working capital | 57.00%-5.58K | -56.77%4.61K | 199.97%8.64K | -125.66%-8.26K | -88.62%2.68K | -251.23%-12.97K | 21.58%10.67K | 0.12%-8.64K | 892.45%32.21K | 146.90%23.51K |
| -Change in receivables | -93.32%149 | 107.00%52 | -131.94%-1.37K | 200.71%5.51K | 91.37%-270 | 480.07%2.23K | -80.34%-743 | 418.95%4.29K | -1,882.61%-5.47K | -668.55%-3.13K |
| -Change in prepaid assets | --0 | --15K | ---15K | -235.34%-1.13K | ---1.13K | --0 | --0 | --0 | 55.22%832 | --0 |
| -Change in payables and accrued expense | 62.33%-5.73K | -191.44%-10.44K | 293.34%25.01K | -134.33%-12.65K | -84.71%4.07K | -316.91%-15.2K | 34.74%11.42K | -145.65%-12.94K | 1,134.34%36.85K | 281.44%26.63K |
| Cash from discontinued investing activities | ||||||||||
| Operating cash flow | -113.59%-95.27K | -27.14%-58.54K | 20.17%-51.03K | 45.80%-176.21K | 81.98%-21.65K | -3.18%-44.6K | 54.29%-46.05K | -4.66%-63.92K | -149.15%-325.14K | -595.22%-120.09K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | ||||||||||
| Cash from discontinued investing activities | ||||||||||
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | 175.00%110K | 25.00%50K | 60K | -45.62%100K | 11.84%20K | -75.90%40K | 40K | 0 | -46.84%183.88K | 17.88K |
| Net issuance payments of debt | 175.00%110K | 25.00%50K | --60K | --100K | --20K | --40K | --40K | --0 | --0 | --0 |
| Net common stock issuance | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | -46.84%183.88K | --17.88K |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 175.00%110K | 25.00%50K | --60K | -45.62%100K | 11.84%20K | -75.90%40K | --40K | --0 | -46.84%183.88K | --17.88K |
| Net cash flow | ||||||||||
| Beginning cash position | -77.31%1.71K | -24.48%10.25K | -98.35%1.28K | -64.58%77.49K | -98.37%2.92K | -86.78%7.52K | -91.39%13.57K | -64.58%77.49K | 6,402.50%218.74K | -23.86%179.7K |
| Current changes in cash | 420.03%14.73K | -41.26%-8.54K | 114.04%8.97K | 46.05%-76.21K | 98.39%-1.65K | -103.75%-4.6K | 94.00%-6.05K | -4.66%-63.92K | -165.59%-141.26K | -491.70%-102.21K |
| End cash Position | 462.75%16.44K | -77.31%1.71K | -24.48%10.25K | -98.35%1.28K | -98.35%1.28K | -98.37%2.92K | -86.78%7.52K | -91.39%13.57K | -64.58%77.49K | -64.58%77.49K |
| Free cash from | -113.59%-95.27K | -27.14%-58.54K | 20.17%-51.03K | 45.80%-176.21K | 81.98%-21.65K | -3.18%-44.6K | 54.29%-46.05K | -4.66%-63.92K | -149.15%-325.14K | -595.22%-120.09K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion with Explanatory Notes | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.